Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis to end anti-infectives R&D
by Michael McCoy
July 13, 2018
| A version of this story appeared in
Volume 96, Issue 29
Novartis has decided to exit antibacterial and antiviral research. About 140 related jobs are being eliminated in Emeryville, Calif.; about 150 jobs will remain in the San Francisco Bay Area at the Novartis Institute for Tropical Diseases and at departments that support efforts focused on difficult targets. The firm says it is talking to other companies about out-licensing its antibiotic programs. They include LYS228, a compound that is being tested in clinical trials for its ability to kill Gram-negative bacteria.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X